Inicio・Lista de Acciones・Intellia Therapeutics Inc

Intellia Therapeutics Inc

Cerrado

SectorSanidad

11.73 -1.59

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

11.68

Máximo

12.17

Métricas clave
By Trading Economics
Ingresos	-107M -203M
Ventas	-7.4M 7.7M
BPA	-0.8
Margen de beneficios	-2,648.714
Empleados	377
EBITDA	-11M -105M

Dividendos
By Acuity
Próximas Ganancias	4 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	280M 1.8B
Apertura anterior	13.32
Cierre anterior	11.73

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

77 / 339 Clasificación en Healthcare

Intellia Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 sept 2026, 19:16 UTC

Intellia Therapeutics Inc shares are lower today, following a notable decline from Wednesday's close amid broader market sentiment after the ECB raised interest rates.

8 sept 2026, 20:07 UTC

News

Social Media

Event

Intellia Therapeutics' shares decline despite FDA accepting its lonvo-z application for Priority Review, targeting a decision by March 2027.

3 sept 2026, 19:16 UTC

Correlated Moves

Intellia Therapeutics shares are lower, reflecting sector pressure and a notable decline in first-quarter results. Correlated asset CRISPR Therapeutics also experienced a downturn.

1 sept 2026, 20:09 UTC

Intellia Therapeutics is lower today, tracking broader market declines amid rising oil prices and increased U.S. Treasury yields, which raise inflation concerns.

31 ago 2026, 23:21 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, recovering from recent declines and positioned above their 20-day moving average.

28 ago 2026, 20:08 UTC

Intellia Therapeutics shares are lower today, continuing a recent downward trend amid rising U.S. Treasury yields and broader market weakness. No specific news was identified.

27 ago 2026, 23:41 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, recovering from an earlier dip and surpassing their 20-day moving average. No specific news was identified.

26 ago 2026, 23:11 UTC

Intellia Therapeutics Inc is higher in after-market hours, reflecting broader market gains. The asset remains above its 20-day moving average and near its one-month range.

25 ago 2026, 20:09 UTC

News

Correlated Moves

Citizens reiterated its Market Outperform rating on Intellia Therapeutics and maintained a $30 price target, contributing to positive sentiment and higher shares.

24 ago 2026, 23:01 UTC

Intellia Therapeutics shares declined after-market, moving lower from Monday's close. The stock remains above its 20-day moving average and near its one-month range.

21 ago 2026, 23:56 UTC

Intellia Therapeutics shares are higher in after-market trading, reflecting a broader market rebound following a recent yield-driven selloff.

20 ago 2026, 19:26 UTC

Correlated Moves

Intellia Therapeutics shares are lower, reflecting declines in the biotechnology sector and the Russell 2000 Index amid challenging market conditions.

19 ago 2026, 20:02 UTC

Correlated Moves

Intellia Therapeutics shares are higher today, reflecting strong investor interest and positive sentiment in the genomics sector, aided by gains in ARK and CRSP.

17 ago 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher, continuing an upward trend since Friday amid positive sentiment in the biotechnology sector and rising long-term Treasury yields.

14 ago 2026, 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc. shares rose in after-market trading, reflecting positive market dynamics. The stock remains above its 20-day moving average.

11 ago 2026, 19:33 UTC

News

Intellia Therapeutics shares are lower after Brookline Capital Markets revised Q2 2026 earnings estimates to a loss of -$0.80 per share.

10 ago 2026, 19:46 UTC

News

Intellia Therapeutics shares rise as analysts boost price targets, with Wedbush raising its target to $17.00 while maintaining a “neutral” rating.

7 ago 2026, 19:26 UTC

News

Correlated Moves

Evercore ISI upgraded Intellia Therapeutics to Outperform and raised its price target to $24, contributing to gains in the stock during Friday's session.

6 ago 2026, 23:06 UTC

Intellia Therapeutics Inc shares are higher in after-market hours, reflecting increased trading activity despite being near the lower end of its one-month range.

4 ago 2026, 19:36 UTC

Correlated Moves

Shares higher today, reflecting gains in SPDR S&P Biotech ETF.

3 ago 2026, 19:36 UTC

Correlated Moves

Intellia Therapeutics Inc. shares are trading higher amid broader small-cap market strength, recovering from an earlier dip during Monday's session.

31 jul 2026, 20:06 UTC

Correlated Moves

Intellia Therapeutics Inc shares are lower today, reflecting broader sector pressures amid rising Treasury yields and inflation concerns.

30 jul 2026, 17:57 UTC

Correlated Moves

News

Shares higher today, supported by Invesco WilderHill Clean Energy ETF.

29 jul 2026, 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive sentiment in small-cap stocks amid broader market trends and the Fed's interest rate decision.

28 jul 2026, 18:36 UTC

Intellia Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

27 jul 2026, 23:46 UTC

Intellia Therapeutics shares are higher in after-market trading, amid positive sentiment in European markets as the DAX rises.

25 jul 2026, 00:02 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive movement in the biotechnology sector amid broader market stability.

24 jul 2026, 13:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in pre-market trading, advancing since Thursday's close despite being significantly below its 20-day moving average.

23 jul 2026, 19:16 UTC

Intellia Therapeutics shares are higher Thursday, recovering from an earlier pullback amid a challenging tech sector backdrop following disappointing earnings from major companies.

22 jul 2026, 23:56 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, though they remain below their 20-day moving average and near the lower end of their one-month range.

Comparación entre iguales

Cambio de precio

Intellia Therapeutics Inc previsión

Consenso

By TipRanks

Compra Moderada

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Intellia Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

77 / 339 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.